These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 24639139)
1. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Terse P; Engelke K; Chan K; Ling Y; Sharpnack D; Saunthararajah Y; Covey JM Int J Toxicol; 2014; 33(2):75-85. PubMed ID: 24639139 [TBL] [Abstract][Full Text] [Related]
2. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Lavelle D; Vaitkus K; Ling Y; Ruiz MA; Mahfouz R; Ng KP; Negrotto S; Smith N; Terse P; Engelke KJ; Covey J; Chan KK; Desimone J; Saunthararajah Y Blood; 2012 Feb; 119(5):1240-7. PubMed ID: 22160381 [TBL] [Abstract][Full Text] [Related]
3. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine. Lau H; Woost PG; Friedrich U; Clausen WHO; Jacobberger JW; Saunthararajah Y Eur J Haematol; 2023 Sep; 111(3):345-355. PubMed ID: 37417197 [TBL] [Abstract][Full Text] [Related]
5. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans. Holleran JL; Beumer JH; McCormick DL; Johnson WD; Newman EM; Doroshow JH; Kummar S; Covey JM; Davis M; Eiseman JL Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472 [TBL] [Abstract][Full Text] [Related]
6. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070 [TBL] [Abstract][Full Text] [Related]
7. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Ebrahem Q; Mahfouz RZ; Ng KP; Saunthararajah Y Oncotarget; 2012 Oct; 3(10):1137-45. PubMed ID: 23087155 [TBL] [Abstract][Full Text] [Related]
8. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786 [TBL] [Abstract][Full Text] [Related]
9. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Eliopoulos N; Cournoyer D; Momparler RL Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951 [TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002 [TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019 [TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204 [TBL] [Abstract][Full Text] [Related]
13. Toxicology and carcinogenesis studies of N,N-dimethyl-p-toluidine (CAS No. 99-97-8) in F344/N rats and B6C3F1/N mice (gavage studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 2012 Sep; (579):1-211. PubMed ID: 23027199 [TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928 [TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287 [TBL] [Abstract][Full Text] [Related]
16. Toxicology and carcinogenesis studies of methylene blue trihydrate (Cas No. 7220-79-3) in F344/N rats and B6C3F1 mice (gavage studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 2008 May; (540):1-224. PubMed ID: 18685714 [TBL] [Abstract][Full Text] [Related]
17. NTP technical report on the toxicity studies of 2- and 4-Methylimidazole (CAS No. 693-98-1 and 822-36-6) administered in feed to F344/N rats and B6C3F1 mice. Chan PC; Toxic Rep Ser; 2004 Apr; (67):1-G12. PubMed ID: 15146214 [TBL] [Abstract][Full Text] [Related]
18. NTP technical report on toxicity studies of urethane in drinking water and urethane in 5% ethanol administered to F344/N rats and B6C3F1 mice. Chan PC Toxic Rep Ser; 1996 Mar; (52):1-91, A1-9, B1-9 passim. PubMed ID: 11803705 [TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289 [TBL] [Abstract][Full Text] [Related]
20. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. Hill B; Jagadeesh D; Pohlman B; Dean R; Parameswaran N; Chen J; Radivoyevitch T; Morrison A; Fada S; Dever M; Robinson S; Lindner D; Smith M; Saunthararajah Y Semin Hematol; 2021 Jan; 58(1):35-44. PubMed ID: 33509441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]